Search research articles
Contact Us
Filters
Showing results (311-320 of 740) with videos related to
Page
of 74
Sort By:
Blood
|
April 16, 2021
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose
Evangelos Terpos, Ioannis P Trougakos, Maria Gavriatopoulou, et al.
Clinical Lymphoma & Myeloma
|
April 14, 2009
Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase
Efstathios Kastritis, Konstantinos Zervas, Panagiotis Repoussis, et al.
Oncology
|
August 11, 2006
Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience
George Bozas, Meletios A Dimopoulos, Efstathios Kastritis, et al.
Intensive Care Medicine
|
April 27, 2017
Diagnostic work-up and specific causes of acute kidney injury
Michael Darmon, Marlies Ostermann, Jorge Cerda, et al.
European Journal of Haematology
|
March 3, 2010
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment
Meletios A Dimopoulos, Dimitrios Christoulas, Maria Roussou, et al.
Haematologica
|
March 3, 2009
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration
Evangelos Terpos, Eirini Katodritou, Evangelos Tsiftsakis, et al.
Vaccines
|
August 6, 2021
High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
Evangelos Terpos, Marianna Politou, Ioannis Ntanasis-Stathopoulos, et al.
Clinical Lymphoma & Myeloma
|
September 1, 2009
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors
Meletios A Dimopoulos, Maria Roussou, Maria Gavriatopoulou, et al.
The Lancet. Oncology
|
June 6, 2018
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
Philippe Moreau, Maria-Victoria Mateos, James R Berenson, et al.
Hemasphere
|
July 19, 2021
Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis
Efstathios Kastritis, Evangelos Terpos, Aimilia Sklirou, et al.
Page
of 74
Search research articles
Search
Showing results (311-320 of 740) with videos related to
Sort By:
Page
of 74
Blood
|
April 16, 2021
Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose
Evangelos Terpos, Ioannis P Trougakos, Maria Gavriatopoulou, et al.
Clinical Lymphoma & Myeloma
|
April 14, 2009
Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase
Efstathios Kastritis, Konstantinos Zervas, Panagiotis Repoussis, et al.
Oncology
|
August 11, 2006
Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience
George Bozas, Meletios A Dimopoulos, Efstathios Kastritis, et al.
Intensive Care Medicine
|
April 27, 2017
Diagnostic work-up and specific causes of acute kidney injury
Michael Darmon, Marlies Ostermann, Jorge Cerda, et al.
European Journal of Haematology
|
March 3, 2010
Lenalidomide and dexamethasone for the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment
Meletios A Dimopoulos, Dimitrios Christoulas, Maria Roussou, et al.
Haematologica
|
March 3, 2009
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration
Evangelos Terpos, Eirini Katodritou, Evangelos Tsiftsakis, et al.
Vaccines
|
August 6, 2021
High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
Evangelos Terpos, Marianna Politou, Ioannis Ntanasis-Stathopoulos, et al.
Clinical Lymphoma & Myeloma
|
September 1, 2009
Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: identification of predictive factors
Meletios A Dimopoulos, Maria Roussou, Maria Gavriatopoulou, et al.
The Lancet. Oncology
|
June 6, 2018
Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study
Philippe Moreau, Maria-Victoria Mateos, James R Berenson, et al.
Hemasphere
|
July 19, 2021
Antibody Response After Initial Vaccination for SARS-CoV-2 in Patients With Amyloidosis
Efstathios Kastritis, Evangelos Terpos, Aimilia Sklirou, et al.
Page
of 74